Cargando…
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
AIM: The role of tumor burden (TB) for patients with non-small cell lung cancer (NSCLC) receiving immunotherapy is still unknown. The aim of this analysis was to analyze the prognostic value of TB in a real-world sample of advanced NSCLC patients. METHODS: Sixty-five consecutive patients with advanc...
Autores principales: | Lenci, Edoardo, Marcantognini, Giulia, Cognigni, Valeria, Lupi, Alessio, Rinaldi, Silvia, Cantini, Luca, Fiordoliva, Ilaria, Carloni, Anna Lisa, Rocchi, Marco, Zuccatosta, Lina, Gasparini, Stefano, Berardi, Rossana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400786/ https://www.ncbi.nlm.nih.gov/pubmed/36046436 http://dx.doi.org/10.37349/etat.2021.00043 |
Ejemplares similares
-
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
por: Pecci, Federica, et al.
Publicado: (2021) -
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
por: Lenci, Edoardo, et al.
Publicado: (2021) -
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives
por: Cognigni, Valeria, et al.
Publicado: (2022) -
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
por: Cantini, Luca, et al.
Publicado: (2021) -
Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study
por: Berardi, Rossana, et al.
Publicado: (2020)